Hemogenyx Pharmaceuticals (LON:HEMO) Sets New 52-Week High – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares hit a new 52-week high during trading on Friday . The company traded as high as GBX 410 ($5.17) and last traded at GBX 400.50 ($5.05), with a volume of 102058 shares trading hands. The stock had previously closed at GBX 1.08 ($0.01).

Hemogenyx Pharmaceuticals Stock Down 2.3 %

The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The business has a 50 day simple moving average of GBX 9.61 and a 200 day simple moving average of GBX 4.26. The stock has a market cap of £5.63 billion, a PE ratio of -42,000.00 and a beta of 3.14.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.